source
- Eli Lilly moves to curb black-market sales of retatrutide amid rising illicit demandEli Lilly announced steps to address the growing black‑market trade of its obesity/diabetes drug retatrutide, which has seen increasing illicit use. The company is working with law‑enforcement and…
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decisionZealand Pharma has agreed to sell its economic interest in rusfertide, a peptide drug being developed by Takeda and Protagonist Therapeutics, for $100 million. The transaction comes as the FDA rev…